A clinical trial to study the effect of the drug megarajanga kirutham in patients having menorrhagia (pitha perumbadu)

Phase II non randomised open clinical evaluation of siddha drug magarajanga kirutham for pitha perumbadu(menorrhagia) in female of age between 15 to 50years patients attending opd at AAGHIM attached with gsmc

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2019/08/020767

Enrollment

Registered

2019-08-19

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N922- Excessive menstruation at puberty

Interventions

Intervention1: Megarajanga kirutham: 15 ml of megarajanga kirutham is administrated twice a day for 9 days Control Intervention1: Nil: Nil

Eligibility

Inclusion criteria

Inclusion criteria: Excessive menstruation prologed menstruation puberty menorrhagia premenoppausal menorrhagis

Exclusion criteria

Exclusion criteria: Fibroid polyp adenomyosis bleeding disorders ovarian feminizing tumour uterine fibroids chocolate cyst hypothyroidism abortion and pregnancy

Design outcomes

Primary

Measure	Time frame
outcome is mainly assessed by reduction in clinical symptoms and by comparing the parameters before and after treatmentTimepoint: 1 year	—

Secondary

Measure	Time frame
Reduced amount of blood flow ia assessed by number of sanitary pads used before and after treatmentTimepoint: 1 year	—

Countries

India

Contacts

Public ContactDr Shalini priya R

Government siddha medical college

nanbu.sumi@gmail.com9443279412

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026